Adaptive Biotechnologies Corp
NASDAQ:ADPT
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Price:
3.99 USD
5%
Updated:
May 14, 2024
Adaptive Biotechnologies Corp
Cash Equivalents
|
Adaptive Biotechnologies Corp
Cash Equivalents Peer Comparison
Comparables:
TMO
DHR
MTD
A
IQV
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
Cash Equivalents
$71.2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash Equivalents
$8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
31%
|
CAGR 10-Years
3%
|
|
|
Danaher Corp
NYSE:DHR
|
Cash Equivalents
$7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash Equivalents
$70.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cash Equivalents
$1.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash Equivalents
$1.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
See Also
What is Adaptive Biotechnologies Corp's Cash Equivalents?
Cash Equivalents
71.2m
USD
71.2m
USD
Based on the financial report for Mar 31, 2024, Adaptive Biotechnologies Corp's Cash Equivalents amounts to 71.2m USD.
What is Adaptive Biotechnologies Corp's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-9%
-9%
Over the last year, the Cash Equivalents growth was -25%. The average annual Cash Equivalents growth rates for Adaptive Biotechnologies Corp have been -26% over the past three years , -9% over the past five years .
You don't have any saved screeners yet
